Substrate-Dependent Inhibition of Human MATE1 by Cationic Ionic Liquids

The multidrug and toxin extruders 1- and 2-K (MATE1 and MATE2-K) are expressed in the luminal membrane of renal proximal tubule cells and provide the active step in the secretion of molecules that carry a net positive charge at physiologic pH, so-called organic cations. The present study tested whet...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of pharmacology and experimental therapeutics 2013-09, Vol.346 (3), p.495-503
Hauptverfasser: Martínez-Guerrero, Lucy J., Wright, Stephen H.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 503
container_issue 3
container_start_page 495
container_title The Journal of pharmacology and experimental therapeutics
container_volume 346
creator Martínez-Guerrero, Lucy J.
Wright, Stephen H.
description The multidrug and toxin extruders 1- and 2-K (MATE1 and MATE2-K) are expressed in the luminal membrane of renal proximal tubule cells and provide the active step in the secretion of molecules that carry a net positive charge at physiologic pH, so-called organic cations. The present study tested whether structurally distinct MATE substrates can display different quantitative profiles of inhibition when interacting with structurally distinct ligands. The tested ligands were three structurally similar cationic ionic liquids (ILs, salts in the liquid state: N-butylpyridinium, NBuPy; 1-methyl-3-butylimidazolium, Bmim; and N-butyl-N-methylpyrrolidinium, BmPy). Uptake was measured using Chinese hamster ovary cells that stably expressed MATE1 or MATE2-K. By trans-stimulation, all three ILs were transported by both MATE transporters. The three ILs also inhibited uptake of three structurally distinct MATE substrates: 1-methyl-4-phenylpyridinium (MPP), triethylmethylammonium (TEMA), and N,N,N-trimethyl-2-[methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino]ethanaminium (NBD-MTMA). MATE1 displayed a higher affinity for the pyridinium-based NBuPy (IC50 values, 2–4 µM) than for either the pyrrolidinium- (BmPy; 20–70 µM) or imidazolium-based ILs (Bmim; 15–60 µM). Inhibition of MPP, TEMA, and NBD-MTMA transport by NBuPy was competitive, with comparable Ki values against all substrates. Bmim also competitively blocked the three substrates but with Ki values that differed significantly (20 µM against MPP and 30 µM against NBD-MTMA versus 60 µM against TEMA). Together, these data indicate that renal secretion of ILs by the human kidney involves MATE transporters and suggest that the mechanism of transport inhibition is ligand-dependent, supporting the hypothesis that the binding of substrates to MATE transporters involves interaction with a binding surface with multiple binding sites.
doi_str_mv 10.1124/jpet.113.204206
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3876781</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022356524287449</els_id><sourcerecordid>1426012676</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-c49674d9d9b179463f3384b664d44dc6d405f5b9859b47e66e33ddfb93d13b283</originalsourceid><addsrcrecordid>eNp1kM1PwkAQxTdGo4ievZkevRT2q9v2YkIQgQTjQTxvurtTWQMt7LYk_PcugkQPXmYmmTdvXn4I3RHcI4Ty_ucamjCxHsWcYnGGOiShJMYEs3PUwZjSmCUiuULX3n9iTDgX7BJdUZZmCUlFB43fWuUbVzQQP8EaKgNVE02rhVW2sXUV1WU0aVdFFb0M5iMSqV00LPYLq6Ppd53ZTWuNv0EXZbH0cHvsXfT-PJoPJ_HsdTwdDmax5pw1oeYi5SY3uSJpHsKUjGVcCcEN50YLw3FSJirPklzxFIQAxowpVc4MYYpmrIseD77rVq3A6BDXFUu5dnZVuJ2sCyv_biq7kB_1VrIsFWlGgsHD0cDVmxZ8I1fWa1guiwrq1kvCqcCEilQEaf8g1a723kF5ekOw3OOXe_xhYvKAP1zc_0530v_wDoL8IIDAaGvBSa8tVBqMdaAbaWr7r_kXsB6UBQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1426012676</pqid></control><display><type>article</type><title>Substrate-Dependent Inhibition of Human MATE1 by Cationic Ionic Liquids</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Martínez-Guerrero, Lucy J. ; Wright, Stephen H.</creator><creatorcontrib>Martínez-Guerrero, Lucy J. ; Wright, Stephen H.</creatorcontrib><description>The multidrug and toxin extruders 1- and 2-K (MATE1 and MATE2-K) are expressed in the luminal membrane of renal proximal tubule cells and provide the active step in the secretion of molecules that carry a net positive charge at physiologic pH, so-called organic cations. The present study tested whether structurally distinct MATE substrates can display different quantitative profiles of inhibition when interacting with structurally distinct ligands. The tested ligands were three structurally similar cationic ionic liquids (ILs, salts in the liquid state: N-butylpyridinium, NBuPy; 1-methyl-3-butylimidazolium, Bmim; and N-butyl-N-methylpyrrolidinium, BmPy). Uptake was measured using Chinese hamster ovary cells that stably expressed MATE1 or MATE2-K. By trans-stimulation, all three ILs were transported by both MATE transporters. The three ILs also inhibited uptake of three structurally distinct MATE substrates: 1-methyl-4-phenylpyridinium (MPP), triethylmethylammonium (TEMA), and N,N,N-trimethyl-2-[methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino]ethanaminium (NBD-MTMA). MATE1 displayed a higher affinity for the pyridinium-based NBuPy (IC50 values, 2–4 µM) than for either the pyrrolidinium- (BmPy; 20–70 µM) or imidazolium-based ILs (Bmim; 15–60 µM). Inhibition of MPP, TEMA, and NBD-MTMA transport by NBuPy was competitive, with comparable Ki values against all substrates. Bmim also competitively blocked the three substrates but with Ki values that differed significantly (20 µM against MPP and 30 µM against NBD-MTMA versus 60 µM against TEMA). Together, these data indicate that renal secretion of ILs by the human kidney involves MATE transporters and suggest that the mechanism of transport inhibition is ligand-dependent, supporting the hypothesis that the binding of substrates to MATE transporters involves interaction with a binding surface with multiple binding sites.</description><identifier>ISSN: 0022-3565</identifier><identifier>EISSN: 1521-0103</identifier><identifier>DOI: 10.1124/jpet.113.204206</identifier><identifier>PMID: 23785176</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>1-Methyl-4-phenylpyridinium - pharmacology ; 4-Chloro-7-nitrobenzofurazan - analogs &amp; derivatives ; 4-Chloro-7-nitrobenzofurazan - pharmacology ; Algorithms ; Animals ; Binding, Competitive - drug effects ; Biological Transport, Active - drug effects ; Cations - pharmacology ; CHO Cells ; Cricetinae ; Cricetulus ; Humans ; Ionic Liquids - pharmacology ; Kinetics ; Metabolism, Transport, and Pharmacogenomics ; Organic Cation Transport Proteins - antagonists &amp; inhibitors ; Organic Cation Transport Proteins - metabolism ; Pyridinium Compounds - pharmacology ; Quaternary Ammonium Compounds - pharmacology</subject><ispartof>The Journal of pharmacology and experimental therapeutics, 2013-09, Vol.346 (3), p.495-503</ispartof><rights>2013 American Society for Pharmacology and Experimental Therapeutics</rights><rights>Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-c49674d9d9b179463f3384b664d44dc6d405f5b9859b47e66e33ddfb93d13b283</citedby><cites>FETCH-LOGICAL-c443t-c49674d9d9b179463f3384b664d44dc6d405f5b9859b47e66e33ddfb93d13b283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23785176$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martínez-Guerrero, Lucy J.</creatorcontrib><creatorcontrib>Wright, Stephen H.</creatorcontrib><title>Substrate-Dependent Inhibition of Human MATE1 by Cationic Ionic Liquids</title><title>The Journal of pharmacology and experimental therapeutics</title><addtitle>J Pharmacol Exp Ther</addtitle><description>The multidrug and toxin extruders 1- and 2-K (MATE1 and MATE2-K) are expressed in the luminal membrane of renal proximal tubule cells and provide the active step in the secretion of molecules that carry a net positive charge at physiologic pH, so-called organic cations. The present study tested whether structurally distinct MATE substrates can display different quantitative profiles of inhibition when interacting with structurally distinct ligands. The tested ligands were three structurally similar cationic ionic liquids (ILs, salts in the liquid state: N-butylpyridinium, NBuPy; 1-methyl-3-butylimidazolium, Bmim; and N-butyl-N-methylpyrrolidinium, BmPy). Uptake was measured using Chinese hamster ovary cells that stably expressed MATE1 or MATE2-K. By trans-stimulation, all three ILs were transported by both MATE transporters. The three ILs also inhibited uptake of three structurally distinct MATE substrates: 1-methyl-4-phenylpyridinium (MPP), triethylmethylammonium (TEMA), and N,N,N-trimethyl-2-[methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino]ethanaminium (NBD-MTMA). MATE1 displayed a higher affinity for the pyridinium-based NBuPy (IC50 values, 2–4 µM) than for either the pyrrolidinium- (BmPy; 20–70 µM) or imidazolium-based ILs (Bmim; 15–60 µM). Inhibition of MPP, TEMA, and NBD-MTMA transport by NBuPy was competitive, with comparable Ki values against all substrates. Bmim also competitively blocked the three substrates but with Ki values that differed significantly (20 µM against MPP and 30 µM against NBD-MTMA versus 60 µM against TEMA). Together, these data indicate that renal secretion of ILs by the human kidney involves MATE transporters and suggest that the mechanism of transport inhibition is ligand-dependent, supporting the hypothesis that the binding of substrates to MATE transporters involves interaction with a binding surface with multiple binding sites.</description><subject>1-Methyl-4-phenylpyridinium - pharmacology</subject><subject>4-Chloro-7-nitrobenzofurazan - analogs &amp; derivatives</subject><subject>4-Chloro-7-nitrobenzofurazan - pharmacology</subject><subject>Algorithms</subject><subject>Animals</subject><subject>Binding, Competitive - drug effects</subject><subject>Biological Transport, Active - drug effects</subject><subject>Cations - pharmacology</subject><subject>CHO Cells</subject><subject>Cricetinae</subject><subject>Cricetulus</subject><subject>Humans</subject><subject>Ionic Liquids - pharmacology</subject><subject>Kinetics</subject><subject>Metabolism, Transport, and Pharmacogenomics</subject><subject>Organic Cation Transport Proteins - antagonists &amp; inhibitors</subject><subject>Organic Cation Transport Proteins - metabolism</subject><subject>Pyridinium Compounds - pharmacology</subject><subject>Quaternary Ammonium Compounds - pharmacology</subject><issn>0022-3565</issn><issn>1521-0103</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1PwkAQxTdGo4ievZkevRT2q9v2YkIQgQTjQTxvurtTWQMt7LYk_PcugkQPXmYmmTdvXn4I3RHcI4Ty_ucamjCxHsWcYnGGOiShJMYEs3PUwZjSmCUiuULX3n9iTDgX7BJdUZZmCUlFB43fWuUbVzQQP8EaKgNVE02rhVW2sXUV1WU0aVdFFb0M5iMSqV00LPYLq6Ppd53ZTWuNv0EXZbH0cHvsXfT-PJoPJ_HsdTwdDmax5pw1oeYi5SY3uSJpHsKUjGVcCcEN50YLw3FSJirPklzxFIQAxowpVc4MYYpmrIseD77rVq3A6BDXFUu5dnZVuJ2sCyv_biq7kB_1VrIsFWlGgsHD0cDVmxZ8I1fWa1guiwrq1kvCqcCEilQEaf8g1a723kF5ekOw3OOXe_xhYvKAP1zc_0530v_wDoL8IIDAaGvBSa8tVBqMdaAbaWr7r_kXsB6UBQ</recordid><startdate>201309</startdate><enddate>201309</enddate><creator>Martínez-Guerrero, Lucy J.</creator><creator>Wright, Stephen H.</creator><general>Elsevier Inc</general><general>The American Society for Pharmacology and Experimental Therapeutics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201309</creationdate><title>Substrate-Dependent Inhibition of Human MATE1 by Cationic Ionic Liquids</title><author>Martínez-Guerrero, Lucy J. ; Wright, Stephen H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-c49674d9d9b179463f3384b664d44dc6d405f5b9859b47e66e33ddfb93d13b283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>1-Methyl-4-phenylpyridinium - pharmacology</topic><topic>4-Chloro-7-nitrobenzofurazan - analogs &amp; derivatives</topic><topic>4-Chloro-7-nitrobenzofurazan - pharmacology</topic><topic>Algorithms</topic><topic>Animals</topic><topic>Binding, Competitive - drug effects</topic><topic>Biological Transport, Active - drug effects</topic><topic>Cations - pharmacology</topic><topic>CHO Cells</topic><topic>Cricetinae</topic><topic>Cricetulus</topic><topic>Humans</topic><topic>Ionic Liquids - pharmacology</topic><topic>Kinetics</topic><topic>Metabolism, Transport, and Pharmacogenomics</topic><topic>Organic Cation Transport Proteins - antagonists &amp; inhibitors</topic><topic>Organic Cation Transport Proteins - metabolism</topic><topic>Pyridinium Compounds - pharmacology</topic><topic>Quaternary Ammonium Compounds - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martínez-Guerrero, Lucy J.</creatorcontrib><creatorcontrib>Wright, Stephen H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martínez-Guerrero, Lucy J.</au><au>Wright, Stephen H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Substrate-Dependent Inhibition of Human MATE1 by Cationic Ionic Liquids</atitle><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle><addtitle>J Pharmacol Exp Ther</addtitle><date>2013-09</date><risdate>2013</risdate><volume>346</volume><issue>3</issue><spage>495</spage><epage>503</epage><pages>495-503</pages><issn>0022-3565</issn><eissn>1521-0103</eissn><abstract>The multidrug and toxin extruders 1- and 2-K (MATE1 and MATE2-K) are expressed in the luminal membrane of renal proximal tubule cells and provide the active step in the secretion of molecules that carry a net positive charge at physiologic pH, so-called organic cations. The present study tested whether structurally distinct MATE substrates can display different quantitative profiles of inhibition when interacting with structurally distinct ligands. The tested ligands were three structurally similar cationic ionic liquids (ILs, salts in the liquid state: N-butylpyridinium, NBuPy; 1-methyl-3-butylimidazolium, Bmim; and N-butyl-N-methylpyrrolidinium, BmPy). Uptake was measured using Chinese hamster ovary cells that stably expressed MATE1 or MATE2-K. By trans-stimulation, all three ILs were transported by both MATE transporters. The three ILs also inhibited uptake of three structurally distinct MATE substrates: 1-methyl-4-phenylpyridinium (MPP), triethylmethylammonium (TEMA), and N,N,N-trimethyl-2-[methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino]ethanaminium (NBD-MTMA). MATE1 displayed a higher affinity for the pyridinium-based NBuPy (IC50 values, 2–4 µM) than for either the pyrrolidinium- (BmPy; 20–70 µM) or imidazolium-based ILs (Bmim; 15–60 µM). Inhibition of MPP, TEMA, and NBD-MTMA transport by NBuPy was competitive, with comparable Ki values against all substrates. Bmim also competitively blocked the three substrates but with Ki values that differed significantly (20 µM against MPP and 30 µM against NBD-MTMA versus 60 µM against TEMA). Together, these data indicate that renal secretion of ILs by the human kidney involves MATE transporters and suggest that the mechanism of transport inhibition is ligand-dependent, supporting the hypothesis that the binding of substrates to MATE transporters involves interaction with a binding surface with multiple binding sites.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23785176</pmid><doi>10.1124/jpet.113.204206</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-3565
ispartof The Journal of pharmacology and experimental therapeutics, 2013-09, Vol.346 (3), p.495-503
issn 0022-3565
1521-0103
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3876781
source MEDLINE; Alma/SFX Local Collection
subjects 1-Methyl-4-phenylpyridinium - pharmacology
4-Chloro-7-nitrobenzofurazan - analogs & derivatives
4-Chloro-7-nitrobenzofurazan - pharmacology
Algorithms
Animals
Binding, Competitive - drug effects
Biological Transport, Active - drug effects
Cations - pharmacology
CHO Cells
Cricetinae
Cricetulus
Humans
Ionic Liquids - pharmacology
Kinetics
Metabolism, Transport, and Pharmacogenomics
Organic Cation Transport Proteins - antagonists & inhibitors
Organic Cation Transport Proteins - metabolism
Pyridinium Compounds - pharmacology
Quaternary Ammonium Compounds - pharmacology
title Substrate-Dependent Inhibition of Human MATE1 by Cationic Ionic Liquids
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T01%3A14%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Substrate-Dependent%20Inhibition%20of%20Human%20MATE1%20by%20Cationic%20Ionic%20Liquids&rft.jtitle=The%20Journal%20of%20pharmacology%20and%20experimental%20therapeutics&rft.au=Mart%C3%ADnez-Guerrero,%20Lucy%20J.&rft.date=2013-09&rft.volume=346&rft.issue=3&rft.spage=495&rft.epage=503&rft.pages=495-503&rft.issn=0022-3565&rft.eissn=1521-0103&rft_id=info:doi/10.1124/jpet.113.204206&rft_dat=%3Cproquest_pubme%3E1426012676%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1426012676&rft_id=info:pmid/23785176&rft_els_id=S0022356524287449&rfr_iscdi=true